Physician profile
Prashant S Patel
NPI 1932333457
$8,920.80
in general payments reported to CMS, 2019-2025
29 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,571 · 2020: $588 · 2021: $810 · 2022: $935 · 2023: $979 · 2024: $910 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,571.38 | 2019-2025 | Watchman Access System, General - Atherectomy, Watchman Flx |
| Medtronic Vascular, INC. | $1,327.21 | 2019 | |
| Edwards Lifesciences Corporation | $1,229.66 | 2019-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $906.17 | 2019-2024 | Xarelto |
| Abbott Laboratories | $478.43 | 2020-2025 | Mitraclip, Gallant, Diamondback Coronary |
| Shockwave Medical, INC | $404.14 | 2020-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $313.13 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $299.51 | 2019-2024 | |
| Medtronic, INC. | $281.49 | 2021-2025 | Ffrangio, Corevalve Evolut R, Onyx Frontier |
| Amarin Pharma, INC. | $263.14 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $229.72 | 2023-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.63 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $175.27 | 2020-2023 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $170.41 | 2021-2023 | Farxiga |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $158.66 | 2019-2025 | |
| Penumbra, INC. | $126.40 | 2025 | Penumbra System |
| Sanofi-Aventis U.S. LLC | $85.65 | 2019-2022 | |
| Daiichi Sankyo INC. | $83.39 | 2024-2025 | Injectafer |
| Amgen INC. | $74.69 | 2019-2024 | Repatha |
| Biotronik INC. | $74.59 | 2025 | Acticor 7 Vr-T Dx, Amvia Edge, Biomonitor |
| Cardiovascular Systems INC. | $63.65 | 2021-2022 | |
| Philips North America LLC | $55.53 | 2022-2025 | IV Other |
| Actelion Pharmaceuticals US, INC. | $21.94 | 2023 | Opsumit, Uptravi |
| Lundbeck LLC | $21.02 | 2019 | |
| Livanova USA, INC. | $20.42 | 2023 | Lifesparc |
| Regeneron Healthcare Solutions, INC. | $17.61 | 2019 | |
| Gilead Sciences, INC. | $14.10 | 2019 | |
| Astellas Pharma US INC | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.